# Paysign

> Paysign is a publicly traded financial technology company that processes plasma donor compensation and pharmaceutical patient affordability payments, alongside corporate disbursements, rewards cards, digital accounts and donor-management software.

- **Founded:** 2001
- **Headquarters:** Henderson, United States
- **Founders:** Mark Newcomer (Co-founder, President and CEO), Daniel Spence (Co-founder and original payments-platform architect; former executive)
- **Products:** Plasma Donor Compensation, Patient Affordability Solutions, Apherion, Paysign Premier, Corporate Disbursement Solutions
- **Notable:** Nasdaq listing in 2018 under PAYS., FY2025 revenue grew 40.5% to $82.03 million., Added 55 net pharmaceutical patient affordability programs in 2025.

## Products & services

- **Plasma Donor Compensation** — Reloadable prepaid donor cards and a partner portal for plasma-center administrators.
- **Patient Affordability Solutions** — Pharmacy copay claims, medical benefits, buy-and-bill cards, patient travel and lodging payments, enrollment portals and analytics.
- **Apherion** — Blood and plasma donor engagement and management software, monetized through licensing, hosting and professional services.
- **Paysign Premier** — Digital bank account offered with banking services provided by Patriot Bank, N.A.
- **Corporate Disbursement Solutions** — Vendor payments, insurance claims and contractor payouts using prepaid cards.
- **Corporate Rewards and Incentives** — Physical and virtual reward cards with customized program design.

## Achievements

- Nasdaq listing in 2018 under PAYS.
- FY2025 revenue grew 40.5% to $82.03 million.
- Added 55 net pharmaceutical patient affordability programs in 2025.
- Reported Q2 2026 revenue growth of 48.1%, with pharmaceutical revenue exceeding plasma revenue.

## Latest updates

- **2026-10** — Announced its third-quarter 2026 earnings call on October 13; no third-quarter results are used in this profile.
- **2026-08** — Reported Q2 2026 revenue of $28.25 million and raised full-year revenue guidance to $114 million-$117 million.
- **2026-08** — June 2026 quarterly filing valued the Gamma contingent earn-out liability at zero, reflecting revenue below the levels needed for its performance thresholds.
- **2026-03** — Reported FY2025 revenue of $82.03 million, with pharmaceutical revenue growing 167.8%.

## Links

- Website: https://paysign.com/
- LinkedIn: https://www.linkedin.com/company/paysign/
- Twitter/X: https://twitter.com/paysign
- Facebook: https://www.facebook.com/paysign/

---

Profile page: https://yespress.io/paysign
Published by YesPress — https://yespress.io
Last updated: 2026-10-25